Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11352MR)

This product GTTS-WQ11352MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11352MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14083MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ6383MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ2082MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ14595MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ9428MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ548MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ2266MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ4572MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW